Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for young leukemia patients: targeted drug added to chemo

NCT ID NCT03571321

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-stage trial is testing whether adding the drug ruxolitinib (Jakafi) to standard chemotherapy is safe for adolescents and young adults (ages 12-39) newly diagnosed with Ph-like acute lymphoblastic leukemia (ALL), an aggressive subtype. The study will enroll 15 participants and look for side effects. If the combination is well-tolerated, it may pave the way for larger studies to see if it improves long-term disease control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ruxolitinib (Jakafi) taken by mouth, combined with standard chemotherapy drugs (cyclophosphamide, cytarabine, and others) given by IV.
What this could lead to
If successful, this could lead to a new treatment option for adolescents and young adults with a hard-to-treat form of leukemia, potentially improving long-term control of the disease.
What could go wrong
This is a very early (Phase 1) trial with only 15 participants, so it is primarily testing safety, not effectiveness. The combination may cause significant side effects, and it is unknown if it will work better than standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like childhood acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA ALL ALL, CHILDHOOD

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas Southwestern Medical Center

    ACTIVE_NOT_RECRUITING

    Dallas, Texas, 75390, United States

  • University of Chicago Medical Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.